Soluble P2X7 Receptor Plasma Levels in Obese Subjects before and after Weight Loss via Bariatric Surgery

Int J Mol Sci. 2023 Nov 25;24(23):16741. doi: 10.3390/ijms242316741.

Abstract

Obesity is a systemic disease frequently associated with important complications such as type 2 diabetes and cardiovascular diseases. It has also been proven that obesity is a disease associated with chronic low-grade systemic inflammation and that weight loss improves this low-grade chronic inflammatory condition. The P2X7 purinergic receptor (P2X7R), belonging to the family of the receptors for extracellular ATP, is a main player in inflammation, activating inflammasome and pro-inflammatory cytokine production. In this study, we evaluated the plasma levels of soluble P2X7R (sP2X7R) measured in a group of obese patients before and one year after bariatric surgery. Furthermore, we evaluated the relation of sP2X7R to inflammatory marker plasma levels. We enrolled 15 obese patients who underwent laparoscopic sleeve gastrectomy, evaluating anthropometric parameters (weight, height, BMI and waist circumference) before and after surgery. Moreover, we measured the plasma levels of inflammatory markers (CRP, TNFα and IL-6) before and after weight loss via bariatric surgery. The results of our study show that one year after bariatric surgery, obese patients significantly decrease body weight with a significant decrease in CRP, TNF-alfa and IL-6 plasma levels. Similarly, after weight loss, obese subjects showed a significant reduction in sP2X7R plasma levels. Moreover, before surgery, plasma levels of sP2X7R were inversely related with those of CRP, TNF-alfa and IL-6. Given the role of P2X7R in inflammation, we hypothesized that, in obese subjects, sP2X7R could represent a possible marker of chronic low-grade inflammation, hypothesizing a possible role as a mediator of obesity complications.

Keywords: BMI; P2X7 receptor; adipose tissue; bariatric surgery; inflammation; obesity.

MeSH terms

  • Bariatric Surgery* / methods
  • Diabetes Mellitus, Type 2* / complications
  • Humans
  • Inflammation / complications
  • Interleukin-6
  • Obesity / complications
  • Obesity / surgery
  • Obesity, Morbid*
  • Receptors, Purinergic P2X7
  • Weight Loss

Substances

  • Receptors, Purinergic P2X7
  • Interleukin-6

Grants and funding

This study was funded by PRIN—Research Projects of National Relevance—by the Italian Minister of University, project #20178YTNWC_004, and by a donation to the University of Padova (grant no. ROSS_PRIV20_01) from SAFAS Group SpA, Altavilla, Vicenza, Italy.